STADA Arzneimittel AG - M&A Activity 2018

News Details

Corporate | 2 February 2018 17:46

STADA Arzneimittel AG:

DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous

02.02.2018 / 17:46

The issuer is solely responsible for the content of this announcement.

Bad Vilbel, February 2, 2018 – The Extraordinary General Meeting of STADA Arzneimittel AG (STADA) on February 2, 2018 with a majority of 99 percent approved the conclusion of the domination and profit and loss transfer agreement (DPLTA) of December 19, 2017 between Nidda Healthcare Holding GmbH as controlling entity and STADA as dependent company.

The DPLTA provides for a recurring compensation payment for the remaining STADA shareholders of Euro 3.82 gross or currently Euro 3.53 net as well as a compensation in the amount of Euro 74.40 per STADA share.

The agreement must be entered into the Commercial Register before it takes effect.

Contact:

STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel /

Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]

Or visit us in the Internet at www.stada.com .

02.02.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language:	English
Company:	STADA Arzneimittel AG
	Stadastraße 2-18
	61118 Bad Vilbel
	Germany
Phone:	+49 (0)6101 603- 113
Fax:	+49 (0)6101 603- 506
E-mail:	[email protected]
Internet:	www.stada.de
ISIN:	DE0007251803, DE0007251845,
WKN:	725180, 725184,
Indices:	MDAX
Listed:	Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange